Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
It affects up to 10 per cent of women of reproductive age around the world
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Subscribe To Our Newsletter & Stay Updated
